BOOKMARK
  • Korean|
  • Chinese|
  • Japanese|
  • Vietnamese
본문내용 바로가기

Aju Business Daily

SEARCH
  • ECONOMY
  • ENTERTAINMENT
  • IT
  • South Korea
  • North Korea
  • WORLD
  • SPORTS
  • LIFESTYLE
  • AUTO MOTIVE
  • OPINION
  • PEOPLE
  • MILITARY
Home > Health > article

Celltrion achieves initial progress in animal testing of candidates for antibody treatment.

Lim Chang-won Reporter(cwlim34@ajunews.com) | Posted : June 1, 2020, 12:06 | Updated : June 1, 2020, 12:06
  • 트위터
  • 페이스북
  • 웨이보

[Courtesy of Celltrion]



SEOUL -- Celltrion, a bio firm involved in a project to develop the treatment of patients infected with a new coronavirus, claimed to have achieved progress in the initial animal testing of candidates for antibody treatment.

Celltrion has embarked on the verification of selected candidates for antibody treatment to see if they can neutralize the coronavirus. The company has conducted animal tests on ferrets.

Symptoms such as coughing have disappeared since the fifth day of drug administration, Celltrion said, adding the virus was reduced by up to 100 times when antibody treatments were administered at high concentrations and lung inflammation was greatly improved.

The company would conduct efficacy and toxicity tests on hamsters, mice and monkeys before starting clinical trials for humans in July. The Korea National Institute of Health, a state research body, has selected Celltrion as a cooperation partner to develop vaccines and medicine.

 

  • Lim Chang-won Reporter
  • email : cwlim34@ajunews.com
© Aju Business Daily & www.ajunews.com Copyright: All materials on this site may not be reproduced, distributed, transmitted, displayed, published or broadcast without the authorization from the Aju News Corporation.
  • twitter
  • facebook
  • weibo
  • link copy
  • LIST
  • TOP

Related news

  • .State watchdog starts screening Celltrions antibody treatment for COVID-19.
    State watchdog starts screening Celltrion's antibody treatme…
  • .Celltrion leaves door open for consignment production of COVID-19 vaccines.
    Celltrion leaves door open for consignment production of COV…
  • .GC Pharmas plasma treatment allowed for actual use in treating COVID-19 patients.
    GC Pharma's plasma treatment allowed for actual use in treat…
  • .Celltrion allowed to go ahead with last-stage clinical test of COVID-19 antibody treatment.
    Celltrion allowed to go ahead with last-stage clinical test …
  • . Celltrion revises deal with U.S. client to ship new rapid COVID-19 antigen test kit.
    Celltrion revises deal with U.S. client to ship new rapid C…

Real Time Photo News

  • .Singer HyunA to end 14-month hiatus with mini-album Im Not Cool.

    Singer HyunA to end 14-month hiatus with mini-album 'I'm Not Cool'

  • .NCSofts global K-pop fan community platform to service original content including songs.

    NCSoft's global K-pop fan community platform to service original content including songs

  • .Singer IU drops teaser image for upcoming full album.

    Singer IU drops teaser image for upcoming full album

  • .Cube Entertainment partners with web comics company to create online video content.

    Cube Entertainment partners with web comics company to create online video content

  • .Sci-fi film starring Song Joong-ki to be reelased on Netflix in February.

    Sci-fi film starring Song Joong-ki to be reelased on Netflix in February

Latest News

more+

  • LA-bound Maersk containership loses some 750 containers overboard in Pacific
  • SK Bioscience selected to manage COVID-19 vaccine distribution in S. Korea
  • S. Korea finalizes official process of imposing 513% tariff on imported rice
  • Verizon becomes first to deploy Samsung's fully virtualized 5G solutions
  • Singer HyunA to end 14-month hiatus with mini-album 'I'm Not Cool'
Aju Business Daily
  • ABOUT US
  • CONTACT US
  • PRIVACY STATEMENT
  • Copyright Policy

Address : Aju News Corporation LEEMA Building, 11th floor, 42, Jong-ro 1-gil, Jongno-gu, Seoul.    Mail : swatchsjp@ajunews.com

Copyright ⓒ 2016 By Ajunews Corporation, All Rights Reserved.

Mobile view